Replies to post #20215 on Biotech Values

[io_io]

MYOG

Isn't this a big unmet need, where everything else failed due to placebo issues ?

OTOH, it's only one of two needed phase IIIs.

[rkrw]

For whatever reason there's been a ton of shorts in myog. So it could be a lot of short covering. otoh the data looks to be best in class, superior efficacy and safety. Actelions tracleer is running at >$500M/year. If the data holds up, the move may well be justified in the long term imo. And as you say this isn't even myog's most important drug. myog bottomed at around $6 bucks I think.